KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Boston Scientific (BSX) Other Operating Expenses (2016 - 2025)

Boston Scientific's Other Operating Expenses history spans 16 years, with the latest figure at $343.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 4.99% year-over-year to $343.0 million; the TTM value through Dec 2025 reached $1.1 billion, down 13.98%, while the annual FY2025 figure was $1.1 billion, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was $343.0 million at Boston Scientific, up from $247.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $500.0 million in Q2 2024 and bottomed at -$22.0 million in Q4 2022.
  • The 5-year median for Other Operating Expenses is $238.0 million (2025), against an average of $193.9 million.
  • The largest annual shift saw Other Operating Expenses crashed 173.33% in 2022 before it skyrocketed 431.82% in 2023.
  • A 5-year view of Other Operating Expenses shows it stood at $30.0 million in 2021, then plummeted by 173.33% to -$22.0 million in 2022, then surged by 431.82% to $73.0 million in 2023, then soared by 394.52% to $361.0 million in 2024, then dropped by 4.99% to $343.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Other Operating Expenses are $343.0 million (Q4 2025), $247.0 million (Q3 2025), and $280.0 million (Q2 2025).